Clinical trials
Lupus clinical trials
Below are recruiting lupus clinical trials, each written for real people, not researchers. We’re tracking 337 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT06475742Enrolling by invitationPhase 3
Long-term safety of cenerimod in lupus patients
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Aurora, ColoradoAges 18–75 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Mesa, ArizonaAges 16 years+ - NCT07276958RecruitingPhase 1
Study of LY4298445 for Lupus and Rheumatoid Arthritis
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
BrisbaneAges 18–55 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65 - NCT03001973Recruiting
Study of Chinese lupus kidney inflammation evidence
This trial is for people who have lupus nephritis, which means lupus affecting the kidneys. It aims to gather high-quality evidence that may help improve how this condition is understood and cared for.
Guangzhou, GuangdongAges 14 years+ - NCT03138941Recruiting
Checking if a lupus control definition fits Asia-Pacific patients
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Adelaide, South AustraliaAges 18 years+ - NCT03276923Recruiting
Pregnancy registry for women with autoimmune disease
This study is a pregnancy and health registry for women with autoimmune (immune system) conditions who are trying to become pregnant or are already pregnant. It helps researchers better understand pregnancy outcomes and health needs in autoimmune disease.
Durham, North CarolinaAges Any age - NCT04449991Recruiting
Repeat kidney biopsy in new lupus kidney disease
This study looks at whether doing a planned second kidney biopsy about 12 months later helps doctors understand and guide treatment for people with newly diagnosed lupus nephritis. You may be put on standard lupus-kidney medications, and the main “test” is the repeat biopsy timing.
StockholmAges 18 years+ - NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT05268289RecruitingPhase 2
Trial for lupus kidney inflammation using LNP023
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Phoenix, ArizonaAges 18–100 - NCT05394922Recruiting
Study of sugar patterns in lupus anti-DNA antibodies
This study looks at the “sugar coating” on anti-DNA antibodies in people with lupus. The goal is to better understand these antibody patterns, which may help improve how lupus is studied or treated in the future.
MontpellierAges 18–80 - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT05538208RecruitingPhase 2
Children with lupus kidney inflammation using mycophenolate
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
San Francisco, CaliforniaAges 8–20 - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90 - NCT05680480RecruitingPhase 2
Telitacicept for active lupus kidney inflammation
This trial tests telitacicept to improve lupus nephritis (inflammation of the kidneys caused by lupus). It targets people with active kidney disease confirmed by biopsy and compares outcomes while you receive standard steroid plus mycophenolate treatment.
Hefei, AnhuiAges 18–75 - NCT05688696RecruitingPhase 2
Testing a drug called orelabrutinib for lupus symptoms in adults
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Bengbu, AnhuiAges 18–75 - NCT05698173Recruiting
Study of lupus and accelerated aging
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
BordeauxAges 18–60 - NCT05859191Recruiting
Study of immune cell markers in people with lupus
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
ToursAges 18 years+ - NCT05927688Recruiting
Using patient reports to adjust treatment for autoimmune diseases
This study looks at whether doctors consider patient “electronic reports” (completed online/phone) when deciding how often to change treatment. It may help improve how well treatment plans match how patients feel over time.
StrasbourgAges 18 years+
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus?
- Yes. Clin2 currently lists 337 recruiting lupus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.